Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults

A phase I clinical trial

Rosalind Rowland The Jenner Institute; University of Oxford; Oxford, UK

Ansar A. Pathan The Jenner Institute; University of Oxford; Oxford, UK

Iman Satti The Jenner Institute; University of Oxford; Oxford, UK

Ian D. Poulton The Jenner Institute; University of Oxford; Oxford, UK

Magali M. L. Matsumiya The Jenner Institute; University of Oxford; Oxford, UK

Megan Whittaker The Jenner Institute; University of Oxford; Oxford, UK

Angela M. Minassian The Jenner Institute; University of Oxford; Oxford, UK

Geraldine A. O’Hara The Jenner Institute; University of Oxford; Oxford, UK

Matthew Hamill The Jenner Institute; University of Oxford; Oxford, UK

Janet T. Scott The Jenner Institute; University of Oxford; Oxford, UK

Stephanie A. Harris The Jenner Institute; University of Oxford; Oxford, UK

Hazel C. Poyntz The Jenner Institute; University of Oxford; Oxford, UK

Cynthia Bateman The Jenner Institute; University of Oxford; Oxford, UK

Joel Meyer The Jenner Institute; University of Oxford; Oxford, UK

Nicola Williams Centre for Statistics in Medicine; Wolfson College Annexe; University of Oxford; Oxford, UK

Sarah C. Gilbert The Jenner Institute; University of Oxford; Oxford, UK

Alison M. Lawrie The Jenner Institute; University of Oxford; Oxford, UK

Adrian V.S. Hill The Jenner Institute; University of Oxford; Oxford, UK

Helen McShane The Jenner Institute; University of Oxford; Oxford, UKCorrespondence[email protected]